Terry R.D., Davies P. Dementia of the Alzheimer type. Annu Rev Neurosci. 1980;3:77–95.
Zhu X.C., Tan L., Wang H.F., et al. Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Annals of translational medicine. 2015;3(3):38.
Lambert M.A., Bickel H., Prince M., et al. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563–569.
van Vliet D., de Vugt M.E., Bakker C., et al. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med. 2013;43(2):423–432.
Stanley K., Walker Z. Do patients with young onset Alzheimer’s disease deteriorate faster than those with late onset Alzheimer’s disease? A review of the literature. International psychogeriatrics. IPA. 2014; 26(12):1945–1953;
Smits L.L., Pijnenburg Y.A., van der Vlies A.E., et al. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2015.
Palasi A., Gutierrez-Iglesias B., Alegret M., et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015;262(5):1238–1246.
Joubert S., Gour N., Guedj E., et al. Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impairment. Cortex. 2016;74:217–232.
Koedam E.L., Lauffer V., van der Vlies A.E., van der Flier W.M., Scheltens P., Pijnenburg Y.A. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401–1408.
Ossenkoppele R., Pijnenburg Y.A., Perry D.C., et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(Pt 9):2732–2749.
Tsuno N., Homma A. What is the association between depression and Alzheimer’s disease? Expert Rev Neurother. 2009 Nov;9(11):1667-76.
Cho H., Jeon S., Kang S.J., et al. Longitudinal changes of cortical thickness in early-versus late-onset Alzheimer’s disease. Neurobiology of aging. 2013;34(7): 1921–e9.
Migliaccio R., Agosta F., Possin K.L., et al. Mapping the Progression of Atrophy in Early and Late- Onset Alzheimer’s Disease. J Alzheimers Dis. 2015; 46:351–364.
Chiaravalloti A., Koch G., Toniolo S., et al. Comparison between Early-Onset and Late-Onset Alzheimer’s Disease Patients with Amnestic Presentation: CSF and (18) F-FDG PET Study. Dementia and geriatric cognitive disorders extra. 2016;6(1):108–119.
Kaiser N.C., Melrose R.J., Liu C., et al. Neuropsychological and neuroimaging markers in early versus late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(7):520–529.
Palasi A., Gutierrez-Iglesias B., Alegret M., et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015; 262:1238–1246.
Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785–796.
Jarmolowicz A.I., Chen H.Y., Panegyres P.K. The patterns of inheritance in early-onset dementia: Alzheimer’s disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2015;30(3):299–306.
Muller U., Winter P., Graeber M.B. A presenilin 1 mutation in the first case of Alzheimer’s disease. Lancet Neurol. 2013;12(2):129–130.
De Luca V., Orfei M.D., Gaudenzi S., Caltagirone C., Spalletta G. Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2016 Oct 29;266(7):599-606. Epub 2015 Dec 29.
Nicolas G., Charbonnier C., Wallon D., et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease. Molecular psychiatry. 2016;21(6):831–836.
Коберская Н.Н. Болезнь Альцгеймера: новые критерии диагностики и терапевтические аспекты в зависимости от стадии болезни. Медицинский Совет, 2017;10:18-24.
Cummings J., Aisen P., DuBois B. Drug development in Alzheimer’s disease: the path to 2025. Cummings et al. Alzheimer’s Research & Therapy. 2016;8:39.
Schmidt R., Ropele S., Ebenbauer B. et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology. 2007;14(1): 2526.
Коберская Н.Н. Клинические, диагностические и терапевтические аспекты умеренных когнитивных нарушений амнестического типа. Медицинский Совет. 2015;5:40-45.
Peskind E.R., Potkin S.G., Pomara N. et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14:704–15.
Porsteinsson A., Grossberg G., Mintzer J., Olin J. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–89.
Reisberg B., Doody R., Stoffler A., Schmitt F. et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003; 348:1333–41.
Reisberg B., Doody R., Stoffler A. et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol. 2006;63:49–54.
Tocco M., Resnick E.M., Graham S. et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology. 2007;14(1):1098.
Winblad B., Jones R., Wirth Y. et al. Memantine in moderate to severe Alzheimer’s disease: meta-analysis of randomized clinical trials. Dement Geriatr Cogn Disord. 2007;24:20–7.
Ito K. et al. Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates. Biochemical and Biophysical Research Communications. 2017;493(1):158-163.
Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014.
Парфенов В.А. Ранняя диагностика и лечение болезни Альцгеймера. Медицинский совет. 2015;5:28-33.